Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 2301 to 2310 of 2586 total matches.

Prosthetic Heart Valves

   
The Medical Letter on Drugs and Therapeutics • Aug 20, 2012  (Issue 1397)
The Medical Letter® On Drugs and Therapeutics Volume 54 (Issue 1397) August 20, 2012 ...
Prosthetic heart valves have been used effectively in patients with mitral and aortic valvular heart disease for more than 50 years, but no replacement valve developed to date is suitable for all types of patients.
Med Lett Drugs Ther. 2012 Aug 20;54(1397):67 |  Show IntroductionHide Introduction

In Brief: New Polio Vaccination Guidance for Travelers

   
The Medical Letter on Drugs and Therapeutics • Sep 01, 2014  (Issue 1450)
Letter® on Drugs and Therapeutics Objective Drug Reviews Since 1959 Volume 56 September 1, 2014 ...
Wild poliovirus has circulated during the previous 12 months in Cameroon, Equatorial Guinea, Ethiopia, Iraq, Israel (also the West Bank and Gaza), Somalia, and Syria, as well as in those countries where polio is still endemic (Afghanistan, Nigeria, and Pakistan). The World Health Organization (WHO) has declared a public health emergency related to the possible spread of polio from affected countries. In response, the Centers for Disease Control and Prevention (CDC) has issued interim guidance for US residents planning travel to and from these countries.Vaccine Recommendations – All travelers...
Med Lett Drugs Ther. 2014 Sep 1;56(1450):84 |  Show IntroductionHide Introduction

In Brief: New Warnings for Janus Kinase Inhibitors

   
The Medical Letter on Drugs and Therapeutics • Oct 04, 2021  (Issue 1634)
skin cancer).1 1. FDA Drug Safety Communication. FDA requires warnings about increased risk ...
The FDA has required updates to the boxed warnings in the labeling of the Janus kinase (JAK) inhibitors tofacitinib (Xeljanz, Xeljanz XR), baricitinib (Olumiant), and upadacitinib (Rinvoq) describing increased risks of major adverse cardiovascular events, malignancy, thrombosis, and death with their use. The new warnings were prompted by the results of a postmarketing safety trial with tofacitinib and were added to the labels of baricitinib and upadacitinib based on the presumption of a class effect. The tofacitinib package insert had contained a boxed warning about an increased...
Med Lett Drugs Ther. 2021 Oct 4;63(1634):160 |  Show IntroductionHide Introduction

COVID-19 Update: Bivalent Pfizer and Moderna Vaccines Authorized for Children ≥6 Months Old (Online Only)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
. COVID update: Bivalent vaccine booster doses authorized for children ≥5 years old. Med Lett Drugs Ther ...
The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these products (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) in children as young as 6 months. The bivalent Pfizer vaccine is authorized for use as the final dose of a 3-dose primary series in children 6 months to 4 years old. The bivalent Moderna vaccine is authorized for use as a booster dose in children 6 months to 5 years old who completed a primary...
Med Lett Drugs Ther. 2022 Dec 12;64(1665):e209-10 |  Show IntroductionHide Introduction

COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023  (Issue 1667)
. Med Lett Drugs Ther 2021; 63:113. 3. RECOVERY Collaborative Group. Tocilizumab in patients admitted ...
The interleukin-6 (IL-6) receptor antagonist tocilizumab (Actemra – Genentech) has been approved by the FDA for IV treatment of COVID-19 in hospitalized adults who are receiving a systemic corticosteroid and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab was previously available for this indication under an Emergency Use Authorization (EUA); it remains available under an EUA for treatment of children 2-17 years old who are hospitalized with COVID-19 and require oxygen support.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):e9   doi:10.58347/tml.2023.1667d |  Show IntroductionHide Introduction

In Brief: New FDA Warning of Pulmonary Aspiration with GLP-1 Receptor Agonists

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024  (Issue 1718)
have been published.1 Randomized, controlled trials evaluating the risk of pulmonary aspiration with these drugs ...
The package inserts of the GLP-1 receptor agonists dulaglutide (Trulicity), exenatide (Byetta, Bydureon BCise), liraglutide (Saxenda, Victoza), and semaglutide (Ozempic, Rybelsus, Wegovy) and the dual glucosedependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) have been updated to include rare postmarketing reports of pulmonary aspiration associated with their use in patients undergoing elective surgery or other procedures requiring general anesthesia or deep sedation who had residual gastric contents despite preoperative...
Med Lett Drugs Ther. 2024 Dec 23;66(1718):201-2   doi:10.58347/tml.2024.1718a |  Show IntroductionHide Introduction

Omlyclo — An Omalizumab Biosimilar Interchangeable with Xolair

   
The Medical Letter on Drugs and Therapeutics • Apr 09, 2025  (Issue 5104)
-letter suffix -igec has no pronunciation or meaning; such suffixes are added to biologic drugs ...
Omlyclo (omalizumab-igec; Celltrion), a biosimilar product interchangeable with the recombinant anti-IgE monoclonal antibody Xolair, has been approved by the FDA for same indications as Xolair (see Table 1). Omlyclo is the first Xolair biosimilar to be approved in the US.
Med Lett Drugs Ther. 2025 Apr 9;67(5104):1-2   doi:10.58347/tml.2025.5104a |  Show IntroductionHide Introduction

Nitroglycerin Patches - Do They Work?

   
The Medical Letter on Drugs and Therapeutics • Jul 14, 1989  (Issue 796)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Transdermal nitroglycerin products commercially available in the USA are listed in the table below. These patches, which look like adhesive bandages, are often applied over the precordium, but they can be attached to any hairless area of the skin, except distal parts of the extremities. Individual patients vary in their absorption of nitroglycerin from the skin; the amounts delivered (the doses) are average figures.
Med Lett Drugs Ther. 1989 Jul 14;31(796):65-6 |  Show IntroductionHide Introduction

Treatment of Hypothermia

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 1994  (Issue 938)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
This winter physicians in many area may see patients suffering from hypothermia. Old age, lack of adequate housing, drug overdose and alcohol ingestion are often prediposing factors, but hypothermia also occurs in healthy young people after prolonged exposure to cold due to incapacitating trauma or cold water immersion. Hypothermia associated with exhaustionduring outdoor sports activities can occur even at relatively mild temperatures.
Med Lett Drugs Ther. 1994 Dec 23;36(938):116-7 |  Show IntroductionHide Introduction

Umbilical Cord Blood for Bone Marrow Transplantation

   
The Medical Letter on Drugs and Therapeutics • Aug 16, 1996  (Issue 981)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
High-dose chemotherapy followed by bone marrow transplantation continues to be widely used in the treatment of malignant diseases (Medical Letter, 37:25, 1995). The source of the transplant has been autologous or allogeneic bone marrow or, more recently, stem and progenitor cells harvested from peripheral blood (Medical Letter, 37:71, 1995). Now, blood taken from the umbilical cord and placenta of a newborn infant is being tried as a source of cells to restore the bone marrow. A single collection of umbilical cord blood contains about as many progenitor cells as most autologous bone...
Med Lett Drugs Ther. 1996 Aug 16;38(981):71-2 |  Show IntroductionHide Introduction